Analysis of the potential for immunosuppression of infants with in-utero and breast milk exposure to antitumor necrosis factor alpha agents: are all agents equally safe?
Authors:
Open Access
- 8 September 2025
- journal article
- Published by Wolters Kluwer Health in International Journal of Women's Dermatology
- Vol. 11 (3) , e220
Abstract
Objective: To assess the safety of tumor necrosis factor inhibitors (TNFi) during pregnancy, specifically in relation to infant infection rates, vaccine efficacy, and vaccine-associated adverse events in infants exposed to TNFi in utero and through breast milk. Data Sources: A comprehensive literature review was conducted using PubMed and Google Scholar. The review included retrospective studies, prospective studies, and systematic reviews published until June 2024, focusing on TNFi exposure during pregnancy and breastfeeding. Study Selections: Studies reporting on infant infection rates, vaccination outcomes, and adverse events following in-utero or breastfeeding exposure to TNFi agents, including certolizumab pegol, adalimumab, infliximab, etanercept, and golimumab. Narrative reviews were excluded, while systematic reviews were considered. Results: The review indicates that gestational exposure to TNFi does not increase the risk of severe infections in infants. Additionally, no significant rise in infections was found in infants exposed to TNFi through breast milk. Vaccination outcomes, including efficacy and adverse events, were comparable between exposed and unexposed infants. However, caution is advised when administering the Bacille Calmette–Guerin vaccine to infants exposed to TNFi, particularly within the first year of life. Conclusion: TNFi appear to be safe during pregnancy and breastfeeding. The data indicate that TNFi does not increase the risk of severe infections or vaccine complications in infants, with the exception of the Bacille Calmette–Guerin vaccine, for which a more cautious approach is recommended. These findings reinforce the use of TNFi in women with inflammatory conditions who are pregnant or breastfeeding, providing benefits to both maternal and fetal health.Keywords
This publication has 37 references indexed in Scilit:
- Placental Transfer of Anti–Tumor Necrosis Factor Agents in Pregnant Patients With Inflammatory Bowel DiseaseClinical Gastroenterology and Hepatology, 2013
- Psoriasis and pregnancy outcomes: A nationwide population-based studyJournal of the American Academy of Dermatology, 2011
- Case Report: Fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's DiseaseJournal of Crohn's and Colitis, 2010
- Tumor Necrosis Factor-α Signaling in MacrophagesCritical Reviews™ in Eukaryotic Gene Expression, 2010
- Anti-TNF therapies: a comprehensive analysis of adverse effects associated with immunosuppressionRheumatology International, 2009
- The role of TNF inhibitors in psoriasis therapy: new implications for associated comorbiditiesF1000 Medicine Reports, 2009
- The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational, multicentre studyAnnals of the Rheumatic Diseases, 2007
- Quality of life in patients with psoriasisHealth and Quality of Life Outcomes, 2006
- Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and MalignanciesJAMA, 2006
- TNF and pregnancy: the paradigm of a complex interactionCytokine & Growth Factor Reviews, 1997